WHAT'S NEW
Announcing New Pancreatic Elastase Assay
BÜHLMANN Laboratories AG is proud to announce the launch of the new fPELA® turbo Automated, Random Access Pancreatic Elastase Test- FDA Exempt. For in vitro Diagnostic Use. Fecal pancreatic elastase is a well-established biomarker to detect pancreatic exocrine insufficiency (PEI) in patients suffering from conditions such as chronic pancreatitis and cystic fibrosis. The concentration of pancreatic elastase levels in feces reflects the level of pancreatic output and correlates with the output of other pancreatic enzymes such as lipase, amylase, and trypsin.
|
|
Announcing four (4) new Application Notes for the BÜHLMANN fCAL® turbo USA assay
Our new hand - 4 of a Kind:
- Roche cobas® c501/502
- Beckman Coulter AU 480
- Siemens ADVIA® XPT
- Abbott Architect® c4000
Contact Jennifer or Collin to schedule an evaluation on your analyzer:
|
|
TECHNICAL NEWS
Announcing New BÜHLMANN Quantum Blue® Reader (QB3)
After almost 12 years, BÜHLMANN will stop technical support and maintenance of its 1st generation Quantum Blue® Reader (Serial Numbers <1000 or 0XXX) by the end of 2020. We would like to point out that we still perform quality control for all Quantum Blue® rapid tests on all corresponding readers, including the 1st generation reader. From January 2021, however, quality control for all Quantum Blue® rapid tests will only be performed on the successor reader models, i.e. Quantum Blue® 2nd generation (SN ≥ 1000) and Quantum Blue® 3rd generation (available Q3 2020).
More news to come in the fall… Contact Jennifer or Collin to learn more:
info@buhlmannlabs.com Or https://buhlmannlabs.com/contact/
|
|
IBDoc® Test
Watch video and read the reviews from Canada.
“IBDoc has quickly become an invaluable tool for close follow-up in my patients with Ulcerative Colitis.”
https://buhlmannlabs.com/products-solutions/gastroenterology/ibdoc/
|
|
UPCOMING EVENTS
Upcoming [Virtual] Congress Participation - AMLI
BUHLMANN supports AMLI (American Association for Medical Laboratory Immunologists) 2020 virtual presentation “The latest on IBD Care utilizing Fecal Calprotectin and Therapeutic Drug Monitoring” tune in:
Monday August 17th @ 4PM EST
https://www.amli.org/2020-annual-meeting/program/
|
|
BUHLMANN collaboration poster High Correlation of the Quantum Blue ® rapid assay with HPLC tandem mass spectrometry for infliximab therapeutic drug monitoring.
“Conclusion: The Quantum Blue ® Infliximab rapid test correlates very well with the LC MS/MS method for infliximab trough level determination Therefore, the rapid test fulfills high comparability to the LC MS/MS method and represents a unique and modern analytical tool, for fast time to result and simplicity of usage in a more patient near medical environment”
|
|
RESOURCES AND CITATIONS
Recent Citations
IBDoc®: from ECCO 2020, IBDoc®, the perfect solution for remote disease monitoring in IBD patients
New Posters: There were two posters presented @ ECCO 2020, on long term use of IBDoc by two IBD nurses from Ireland and UK, respectively. I am very happy to see the impact IBDoc is having for the IBD patients" 20-Sugrue & 20 Avery.
After 5 years of market presence, long term data about the impact of IBDoc® usage in clinical routine are beginning to emerge. Improving quality of life of IBD patients is extremely important, developing tools to allow patients to have a higher sense of control over their disease is now a must, especially for chronic diseases. Kathleen Sugrue assessed this in her poster at ECCO 2020.
On the same topic, an internal audit was conducted at Dorset County Hospital to evaluate the efficiency of IBDoc®, which is used there since 2016. Pearl Avery presented the audit findings in her ECCO 2020 poster to better assess the benefit for patients and hospitals. The study is a retrospective evaluation of the most recent results generated with IBDoc®. Correlation between fecal calprotectin and endoscopy or patient disease state was then evaluated.
Recent Citations
Updated for the one and only, BÜHLMANN Neuroimmunology assays:
|
|
PRODUCT HIGHLIGHTS
European External Quality Assessment Scheme for Basophil Activation Test
We are pleased to inform you that the first External Quality Assessment (EQA) Scheme for Basophil Activation Test is now available at INSTAND e.V. The European EQA has been already offered to a set of laboratories in 2019 to evaluate the feasibility of BAT testing. It`s an honor to share with you the extremely positive feedback with a pass rate of about 90% and satisfaction of all BÜHLMANN BAT customers who participated.
INSTAND is providing non-stabilized EDTA whole blood material from normal blood donor and bee/wasp allergic patients, that can be easily assessed by combination of the Flow CAST® kit for Basophil Activation Testing (BAT; FK-CCR), or the CAST® ELISA (EK-CAST) and the specific CAST® allergens for bee and wasp (BAG2-I1 honey bee venom and BAG2-I3 yellow jacket venom).
Learn more about Flow CAST
https://buhlmannlabs.com/products-solutions/cellular-allergy/flow-cast/
Learn More information about blood basophil stability
https://buhlmannlabs.com/category/allergy-technical-news/
Learn More information about the EQA Scheme No. 653 Basophil Activation Test from INSTAND
Learn More details about the EQA program, how to simply register and get samples
https://www.instand-ev.de/en/eqas/eqa-program.html
Video Interview about the External Quality Assessment Scheme for the Basophil Activation Test
|
Buhlmann Diagnostics Corp. © All rights reserved